Can one device do the job of two? TAVR study tests simpler artery closure

NCT ID NCT06871774

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using just one Perclose device to close the artery after TAVR is as safe and effective as the usual two devices. Researchers will measure bleeding time and complications in 300 adults undergoing TAVR. The goal is to see if a simpler approach can reduce procedure time and risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Perclose vascular closure device

What this could lead to

If one device works as well as two, it could simplify the TAVR procedure, reduce costs, and shorten recovery time.

What could go wrong

This is a small, early-stage trial focused on procedural technique, not a new treatment. Using one device might increase the risk of bleeding or complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSCATHETER AORTIC VALVE REPLACEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aortic Valve Disease aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aurora St. Luke's Medical Center

    RECRUITING

    Milwaukee, Wisconsin, 53215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••